Genkyotex picks out silver linings from failed PhII, braces for pivotal study in primary biliary cholangitis
Genkyotex’s Phase II primary biliary cholangitis trial was mainly supposed to measure reduction in gamma glutamyl transpeptidase (CGT). But that may not be obvious if …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
